Newsroom

Sorted by: Latest

-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Moderate Buffer UCITS ETF - May 15.09.2026 GMAY.LN IE000P0FL8E3 1,350,002.00 USD  54,675,053.25   40.500  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest Nasdaq-100 Moderate Buffer UCITS ETF - September 15.09.2026 QSEP.LN IE000FQ808R5  350,002.00 USD   8,808,572.08   25.167  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Indxx Global Aerospace & Defence UCITS ETF 15.09.2026 MISL.LN IE000NVDQXE1 4,525,002.00 USD 148,184,291.70   32.748  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share FIRST TRUST BLOOMBERG GLOBAL SEMICONDUCTOR SUPPLY CHAIN UCITS ETF 15.09.2026 CHPS.LN IE000KXTLDE2  775,002.00 USD  34,948,893.89   45.095  ...
-

Sling Therapeutics Announces First Patients Dosed in Global Phase 3 ORBIT Pivotal Trial of Linsitinib for Thyroid Eye Disease

ANN ARBOR, Mich.--(BUSINESS WIRE)--Sling Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the first and only late-stage oral small-molecule therapy for thyroid eye disease (TED), today announced the first patients have been dosed in the global Phase 3 ORBIT pivotal trial, a global, randomized, double-masked, placebo-controlled study evaluating the efficacy and safety of linsitinib, an oral small molecule inhibitor of the insulin-like growth factor-1 receptor (IGF-1R), in...
-

Perpetuals.com Files Annual Report, Posting Increase in Total Assets to $65 Million and Outlining Strategy to Build an AI-Powered Financial Markets Ecosystem

SAN FRANCISCO--(BUSINESS WIRE)--Perpetuals.com Ltd. (NASDAQ: PDC) today announced that it has filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission, reporting financial results for the fiscal year ended April 30, 2026. Total assets reached $65.2 million as of April 30, 2026, up more than 50-fold from the prior year, reflecting the company's transformation to a fintech company that pairs proprietary AI with regulated market infrastructure to open global markets to...
-

SelectView Appoints Janice Newland as Director of Sales and Business Development

ST. LOUIS--(BUSINESS WIRE)--SelectView, a trusted construction technology partner specializing in purpose-built solutions that help Trimble Viewpoint Vista and Spectrum users turn complex ERP data into actionable business insights including reporting, and dashboard solutions, announced today that Janice Newland has joined the company as Director of Sales and Business Development. Her appointment was effective August 31, 2026. Newland will lead SelectView’s sales and business development efforts...
-

Harris Poll: 70% of Gen Z Healthcare Workers Look to Leave as U.S. Faces Critical Healthcare Workforce Shortage, Commissioned by Workforce Edge

HERNDON, Va.--(BUSINESS WIRE)--The 2026 Healthcare Workforce Barometer conducted by The Harris Poll finds that more than half of the healthcare workforce is still looking to leave....
-

Survey: Limited Partner Interest in Alternatives Hits 5-Year High, Fund Managers Back in Favor

BOSTON--(BUSINESS WIRE)--Dynamo Software today released comprehensive results from its 5th annual survey of global Limited Partners (LPs)....
-

Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Anne C. Whitaker, to the company’s Board of Directors (the Board). Ms. Whitaker is a seasoned biopharmaceutical executive and experienced board director who brings deep commercial and operational expertise, as well as a proven track record of driving growth and transformation across global pharmaceutical and biotechnology organizations. “Anne joins our Board at a defining time for...